HRS 8427
Alternative Names: HRS-8427Latest Information Update: 18 Sep 2025
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Urinary anti-infective agents
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Pyelonephritis; Urinary tract infections
- Phase II Nosocomial pneumonia; Ventilator associated pneumonia
- Phase I Gram-negative infections; Lung disorders
Most Recent Events
- 15 Aug 2025 Jiangsu HengRui Medicine completes a phase I pharmacokinetics trial (In volunteers) in China (Parenteral, Injection) (NCT07073157)
- 18 Jul 2025 Jiangsu HengRui Medicine plans a phase I pharmacokinetics trial (In volunteers) in China (Parenteral, Injection) in July 2025 (NCT07073157)
- 15 Jul 2025 Jiangsu HengRui Medicine initiates a phase I pharmacokinetics trial (In volunteers) in China (Parenteral, Injection) (NCT07073157)